European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading

MT Newswires Live06-24 23:15

European equities traded in the US as American depositary receipts were lower late Wednesday morning, falling 0.83% to 1,868.68 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by 3D printer company Materialise (MTLS) and medical device maker EDAP TMS (FOCL), which rose 5.5% and 4.8% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and consumer goods company Unilever (UL), which were up 1.7% and 1.3% respectively.

The decliners from continental Europe were led by biopharmaceutical firm Cellectis (CLLS) and petroleum refiner Equinor (EQNR), which dropped 5.4% and 3.5% respectively. They were followed by oil and gas company Eni (E) and telecommunications company Ericsson (ERIC), which were down 3.1% and 1.8% respectively.

The gainers from the UK were led by Silence Therapeutics (SLN) and Trinity Biotech (TRIB), which surged 15% and 9.3% respectively. They were followed by Biodexa Pharmaceuticals (BDRX) and medical device maker Smith & Nephew (SNN), which advanced 4.1% and 2.4% respectively.

The decliners from the UK and Ireland were led by Akari Therapeutics (AKTX) and Autolus Therapeutics (AUTL), which fell 8.7% and 3.5% respectively. They were followed by oil and gas company BP (BP) and Mereo BioPharma Group (MREO), which lost 3.1% and 2.9% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment